Wentilactone A Reverses the NF-κB/ECM1 Signaling-Induced Cisplatin Resistance through Inhibition of IKK/IκB in Ovarian Cancer Cells.
Cuiting LvChunxia RenYinjue YuHuijing YinCaiguo HuangGong YangYang HongPublished in: Nutrients (2022)
Wentilactone A (WA) is a tetranorditerpenoid isolated from marine algae. We previously found that WA inhibited cancer cell proliferation with little toxicity. In this study, we show that high expression of extracellular matrix protein-1 (ECM1) promotes cancer cell cisplatin resistance, and the secreted ECM1 activates normal fibroblasts (NFs) to transform cells with characteristics of cancer-associated fibroblasts (CAFs). Transcription of the ECM1 gene is regulated largely by NF-κB through EP881C/T-EP266C binding sites. WA supresses the phosphorylation of NF-κB through inhibition of the upstream IKK/IκB phoshorylation to block the expression of ECM1, which reverses the cisplatin-induced activation of NF-κB/ECM1. On the contrary, cisplatin facilitates phosphorylation of NF-κB to enhance the expression of ECM1. These results highlight ECM1 as a potential target for treatment of cisplatin-resistant cancers associated with the ECM1 activated signaling. In addition, WA reverses cisplatin resistance by targeting both tumor cells and the tumor microenvironment through IKK/IκB/NF-κB signaling to reduce the expression of the ECM1 protein.
Keyphrases
- extracellular matrix
- signaling pathway
- lps induced
- poor prognosis
- pi k akt
- oxidative stress
- nuclear factor
- cell proliferation
- binding protein
- induced apoptosis
- cell cycle arrest
- transcription factor
- long non coding rna
- inflammatory response
- risk assessment
- genome wide
- protein protein
- amino acid
- combination therapy
- small molecule
- endoplasmic reticulum stress
- protein kinase
- human health
- copy number
- genome wide identification